Trial Profile
A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Imatinib
- Indications Choroidal neovascularisation
- Focus Adverse reactions
- 24 Oct 2014 New trial record